Immunopathological factors for vertical transmission of HIV-1. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Immunopathological factors for vertical transmission of HIV-1.

Pathobiology. 2000 Mar-Apr;68(2):53-67. Unique Identifier : AIDSLINE MED/20340758
Edgeworth RL; Ugen KE; Department of Medical Microbiology and Immunology, University of; South Florida College of Medicine, Tampa, FL 33612, USA.

Abstract: With the global rise in human immunodeficiency virus-1 (HIV-1) infection in women of childbearing age, there has also been an alarming rise in the number of mother-to-child transmissions of HIV-1. Although drug therapies such as zidovudine as well as nevirapine have been demonstrated to significantly decrease the incidence of vertical transmission of HIV-1, these therapeutic regimens are still not widely available in some developing countries where maternal-to-child transmission of HIV-1 continues to occur at an alarming rate. Therefore, the continued studies of mechanisms and correlates of vertical transmission of HIV-1 are warranted. The current status of immunological and virological correlates of vertical transmission are summarized in this review. In addition, information concerning recent therapeutic agents for the prevention of HIV-1 vertical transmission is presented. Copyright 2000 S. Karger AG, Basel

Keywords: JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC Adult Anti-HIV Agents/THERAPEUTIC USE *Disease Transmission, Vertical/PREVENTION & CONTROL Female Gestational Age Human HIV Infections/IMMUNOLOGY/PATHOLOGY/PREVENTION & CONTROL/ *TRANSMISSION HIV Seropositivity/EPIDEMIOLOGY HIV-1/*IMMUNOLOGY Infant Infant, Newborn Nevirapine/THERAPEUTIC USE Pregnancy Pregnancy Complications, Infectious/DRUG THERAPY Risk Factors Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. World Health Zidovudine/THERAPEUTIC USE

KWDjournalarticlereviewreview,academicadultanti-hivagents/therapeuticuseKWDdiseasetransmission,vertical/prevention&controlfemalegestationalagehumanhivinfections/immunology/pathology/prevention&control/KWDtransmissionhivseropositivity/epidemiologyhiv-1/KWDimmunologyinfantinfant,newbornnevirapine/therapeuticusepregnancypregnancycomplications,infectious/drugtherapyriskfactorssupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDworldhealthzidovudine/therapeuticuse
001130
A00B1212

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .